Cargando…

Aptamer-siRNA Chimeras: Discovery, Progress, and Future Prospects

Synthetic nucleic acid ligands (aptamers) have emerged as effective delivery tools for many therapeutic oligonucleotide-based drugs, including small interfering RNAs (siRNAs). In this review, we summarize recent progress in the aptamer selection technology that has made possible the identification o...

Descripción completa

Detalles Bibliográficos
Autores principales: Kruspe, Sven, Giangrande, Paloma H.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2017
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5618303/
https://www.ncbi.nlm.nih.gov/pubmed/28792479
http://dx.doi.org/10.3390/biomedicines5030045
_version_ 1783267155876249600
author Kruspe, Sven
Giangrande, Paloma H.
author_facet Kruspe, Sven
Giangrande, Paloma H.
author_sort Kruspe, Sven
collection PubMed
description Synthetic nucleic acid ligands (aptamers) have emerged as effective delivery tools for many therapeutic oligonucleotide-based drugs, including small interfering RNAs (siRNAs). In this review, we summarize recent progress in the aptamer selection technology that has made possible the identification of cell-specific, cell-internalizing aptamers for the cell-targeted delivery of therapeutic oligonucleotides. In addition, we review the original, proof-of-concept aptamer-siRNA delivery studies and discuss recent advances in aptamer-siRNA conjugate designs for applications ranging from cancer therapy to the development of targeted antivirals. Challenges and prospects of aptamer-targeted siRNA drugs for clinical development are further highlighted.
format Online
Article
Text
id pubmed-5618303
institution National Center for Biotechnology Information
language English
publishDate 2017
publisher MDPI
record_format MEDLINE/PubMed
spelling pubmed-56183032017-09-29 Aptamer-siRNA Chimeras: Discovery, Progress, and Future Prospects Kruspe, Sven Giangrande, Paloma H. Biomedicines Review Synthetic nucleic acid ligands (aptamers) have emerged as effective delivery tools for many therapeutic oligonucleotide-based drugs, including small interfering RNAs (siRNAs). In this review, we summarize recent progress in the aptamer selection technology that has made possible the identification of cell-specific, cell-internalizing aptamers for the cell-targeted delivery of therapeutic oligonucleotides. In addition, we review the original, proof-of-concept aptamer-siRNA delivery studies and discuss recent advances in aptamer-siRNA conjugate designs for applications ranging from cancer therapy to the development of targeted antivirals. Challenges and prospects of aptamer-targeted siRNA drugs for clinical development are further highlighted. MDPI 2017-08-09 /pmc/articles/PMC5618303/ /pubmed/28792479 http://dx.doi.org/10.3390/biomedicines5030045 Text en © 2017 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (http://creativecommons.org/licenses/by/4.0/).
spellingShingle Review
Kruspe, Sven
Giangrande, Paloma H.
Aptamer-siRNA Chimeras: Discovery, Progress, and Future Prospects
title Aptamer-siRNA Chimeras: Discovery, Progress, and Future Prospects
title_full Aptamer-siRNA Chimeras: Discovery, Progress, and Future Prospects
title_fullStr Aptamer-siRNA Chimeras: Discovery, Progress, and Future Prospects
title_full_unstemmed Aptamer-siRNA Chimeras: Discovery, Progress, and Future Prospects
title_short Aptamer-siRNA Chimeras: Discovery, Progress, and Future Prospects
title_sort aptamer-sirna chimeras: discovery, progress, and future prospects
topic Review
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5618303/
https://www.ncbi.nlm.nih.gov/pubmed/28792479
http://dx.doi.org/10.3390/biomedicines5030045
work_keys_str_mv AT kruspesven aptamersirnachimerasdiscoveryprogressandfutureprospects
AT giangrandepalomah aptamersirnachimerasdiscoveryprogressandfutureprospects